HC Wainwright Estimates MannKind’s Q1 Earnings (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) – HC Wainwright lowered their Q1 2026 earnings per share estimates for MannKind in a research note issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn ($0.06) per share for the quarter, down from their previous estimate of ($0.03). HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for MannKind’s current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for MannKind’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.19) EPS and FY2028 earnings at ($0.09) EPS.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The business had revenue of $111.96 million during the quarter, compared to analysts’ expectations of $99.85 million. MannKind had a negative return on equity of 11.21% and a net margin of 1.68%.The company’s revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.03 earnings per share.

MNKD has been the topic of a number of other reports. Mizuho decreased their price target on MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Wedbush decreased their price target on MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. Wall Street Zen cut MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Wells Fargo & Company decreased their price target on MannKind from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Finally, Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 15th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.56.

MannKind Stock Performance

Shares of MannKind stock opened at $2.70 on Monday. The firm has a market capitalization of $833.76 million, a price-to-earnings ratio of 135.07 and a beta of 1.04. MannKind has a fifty-two week low of $2.23 and a fifty-two week high of $6.51. The stock has a 50 day moving average of $3.09 and a 200 day moving average of $4.70.

Insider Activity

In related news, CEO Michael Castagna acquired 100,000 shares of MannKind stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $2.59 per share, for a total transaction of $259,000.00. Following the completion of the purchase, the chief executive officer owned 2,575,911 shares in the company, valued at approximately $6,671,609.49. The trade was a 4.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.60% of the company’s stock.

Institutional Trading of MannKind

Several hedge funds have recently modified their holdings of MNKD. AQR Capital Management LLC raised its stake in shares of MannKind by 19.8% in the first quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 9,160 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of MannKind by 3.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company’s stock valued at $1,059,000 after acquiring an additional 6,079 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of MannKind by 8.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company’s stock valued at $3,374,000 after acquiring an additional 53,202 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of MannKind by 42.7% in the second quarter. JPMorgan Chase & Co. now owns 1,352,017 shares of the biopharmaceutical company’s stock valued at $5,057,000 after acquiring an additional 404,842 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of MannKind by 84.8% in the second quarter. Prudential Financial Inc. now owns 37,381 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 17,150 shares in the last quarter. 49.55% of the stock is currently owned by institutional investors and hedge funds.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.